Commercialisation

Business Model

The benefit of LTR’s business model is a significantly reduced time to approval and lower cost, even when compared with traditional drug repurposing strategies as shown below:

The Global ED Market is expected to generate revenue of USD $7.10 BN by the end of 2026

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.